CoChat

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., Ratcliffe, S. · 2013 · Journal of Neurology

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Central neuropathic pain (CNP) occurs in many multiple sclerosis (MS) patients. The provision of adequate pain relief to these patients can very difficult. Here we report the first phase III placebo-controlled study of the efficacy of the endocannabinoid system modulator delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (USAN name, nabiximols; Sativex, GW Pharmaceuticals, Salisbury, Wiltshire, UK), to alleviate CNP. Patients who had failed to gain adequate analgesia from existing medication were treated with THC/CBD spray or placebo as an add-on treatment, in a double-blind manner, for 14 weeks to investigate the efficacy of the medication in MS-induced neuropathic pain. This parallel-group phase of the study was then followed by an 18-week randomized-withdrawal study (14-week open-label treatment period plus a double-blind 4-week randomized-withdrawal phase) to investigate time to treatment failure and show maintenance of efficacy. A total of 339 patients were randomized to phase A (167 received THC/CBD spray and 172 received placebo). Of those who completed phase A, 58 entered the randomized-withdrawal phase. The primary endpoint of responder analysis at the 30 % level at week 14 of phase A of the study was not met, with 50 % of patients on THC/CBD spray classed as responders at the 30 % level compared to 45 % of patients on placebo (p = 0.234). However, an interim analysis at week 10 showed a statistically significant treatment difference in favor of TH…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00415-012-6739-4

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Bonica JJ (1991) Introduction Semantic, Epidemiologic, and Educational Issues. In: Casey KL (ed) Pain and Central Nervous System Disease The Central Pain Syndromes. Raven Press, Ltd. New York 21

Cited by

See all 298

Metadata

Authors
Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., & Ratcliffe, S.
Affiliations
  • St Bartholomew's Hospital (GB)
  • James Paget University Hospital (GB)
  • MAC Clinical Research (United Kingdom) (GB)
Corresponding author
Ratcliffe, S.
Venue
Journal of Neurology
Published
2012-11-21
Volume
260
Issue
4
Pages
984-997
ISSN
  • 0012-1037 (ISSN-L)
  • 0340-5354
  • 1432-1459
OpenAlex
W1980502203
Cited by
298
References
29
Citations by year
2026: 9 · 2025: 36 · 2024: 17 · 2023: 19 · 2022: 38 · 2021: 23 · 2020: 34 · 2019: 18 · 2018: 28 · 2017: 14 · 2016: 15 · 2015: 17 · 2014: 19 · 2013: 9
FWCI
10.57
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
GW Pharmaceuticals
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
central pain, multiple sclerosis, nabiximols, treatment failure, sleep quality, analgesia, responder analysis, Sativex, treatment efficacy and safety, adverse events, sleep disorders
MeSH terms
Administration, Oral, Adult, Analysis of Variance, Cannabidiol, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Sclerosis, Neuralgia, Pain Measurement, Dronabinol, Treatment Outcome, Analgesics, Non-Narcotic, Kaplan-Meier Estimate, Administration, Mucosal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. https://app.cochat.ai/papers/10.1007/s00415-012-6739-4
The paper
Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., & Ratcliffe, S. (2013). A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology. https://doi.org/10.1007/s00415-012-6739-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.